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ABSTRACT 
 
Systemic Sublingual Delivery of Octreotide Acetate Utilizing Low-Current Oral 
Electrical Stimulation in Rabbits. (August 2012) 
Christina Marie Bolch, B.S., Texas A&M University; 
M.E., Texas A&M University 
Chair of Advisory Committee: Dr. John C. Criscione 
A sublingual electronic pill is a novel device designed to enhance delivery of drugs/ 
biologics sublingually utilizing low-current electrical stimulation. Our primary aim 
was to explore safe limits of oral electrical stimulus in animals and conduct a 
randomized, sham-controlled animal study to quantify benefits of electrical 
stimulation on sublingual absorption of octreotide (a small peptide) as a first step in 
the development of this technology.  
A system to deliver low-current alternating and direct current stimuli to the oral 
mucosa of rabbits was constructed, and five groups were studied to determine the 
significance of sublingual octreotide diffusion in the presence of three different 
electrical stimulation scenarios: +DC (+4 mA), -DC (-4 mA), and AC (2 mA peak-
to-peak, 20 Hz square wave). These were compared to an Oral Baseline Absorption 
Group (sublingual diffusion in the absence of stimulation) to determine statistical 
significance of electrical stimulus; and a Subcutaneous Control Group (bolus 
injection) to discern therapeutic significance. 
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+DC stimulation (4mA) increased serum concentration 28x with high statistical 
significance (p-value=0.0008). -DC stimulation (-4mA) increased serum 
concentration by 19x with borderline significance (p=0.032). AC (20 Hz) stimulus 
(2mA peak-peak) increased serum concentration by 10x, but was not statistically 
significant.  
The absorption rate of octreotide was also calculated for each group and compared 
at t=10 minutes and t=30 minutes. The absorption rate of the +DC group was 28x 
greater than that of Baseline Group and was statistically significant (p=0.0008). The 
absorption rate of the -DC group was 19x greater than that of the Baseline Group 
and was statistically significant (p=0.032). The absorption rate of the AC group was 
10x greater than the Baseline Group but was not statistically significant (p=0.135). 
While none of the sublingual groups reached therapeutically significant serum 
concentrations, therapeutic levels of sublingually-delivered octreotide could 
potentially be achieved by extending octreotide exposure and stimulation time, 
coupled with utilizing sublingual octreotide in higher concentrations. This research 
was a necessary first step in successful realization of the SEP device. 
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NOMENCLATURE 
AAALAC Association for the Assessment and Accreditation of Laboratory 
Animal Care, International 
AC  Alternating Current 
AD620 Instrumental amplifier  
ARO  Army Research Office 
AUP  Animal Use Protocol 
BNC  Bayonet Neill-Concelman/British Naval Connector 
BVr  Blood volume (rabbit) 
BVh  Blood volume (human) 
BWr  Rabbit body weight 
C0  Initial concentration 
C30  Concentration at 30 mins 
cpm  Counts per minute 
DARPA Defense Advanced Research Projects Agency 
DC  Direct Current 
FDA  Food and Drug Administration 
Hz  Hertz 
IACUC Institutional Animal Care and Use Committee 
IM  Intramuscular 
Ir  Current across the rabbit 
k  Elimination rate constant 
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kΩ  Kilohms 
LARR  Laboratory Animal Resources and Research Facility 
LM741 Operational amplifier 
mA  Milliamperes 
MCGs  Membrane Coating Granules 
mcg  Micrograms 
ml  Milliliters 
ms  Milliseconds 
µs  Microseconds 
pH  Potential Hydrogen 
PI  Principal Investigator 
RG  Gain resistor 
RIA  Radioimmunoassay 
RNA  Ribonucleic Acid 
Rr  Resistance of rabbit 
SEP  Sublingual Electronic Pill 
SPF  Specific Pathogen Free 
Stim  Stimulation/stimulated 
SubQ  Subcutaneous 
T  Period (for alternating current) 
t1/2  Half-life 
TAMU Texas A&M University 
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v  Volts 
Vd  Volume of distribution 
Vdh  Volume of distribution (human) 
Vdr  Volume of distribution (rabbit) 
Vin  Voltage input into Precision Current Source 
VIPoma Vasoactive intestinal peptide-oma 
Vr  Voltage across the rabbit 
Vs  Voltage source for instrumental amplifier 
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1. INTRODUCTION: THE NEED FOR A SUBLINGUAL ELECTRONIC 
PILL DEVICE  
A sublingual electronic pill (SEP, SEP Technologies, Inc.) is a novel device that is 
designed to enhance the delivery of drugs and/or biologics in a sublingual transmucosal 
format with the aid of low-current electrical stimulation. This device may be capable of 
eliminating the need for intravenous injections and their associated discomfort and 
challenging supply logistics. This research is a first step in the development of this 
technology. The primary aim of this research was to explore the safe limits of oral 
electrical stimulus in animals and conduct a prospective, randomized, sham controlled, 
animal study to quantitatively establish the benefit of electrical stimulation on 
absorption of octreotide acetate (a small peptide).  
1.1 Motivation for Department of Defense Sponsorship Study  
Many biologics, such as small interfering RNA and monoclonal antibodies, cannot be 
administered orally (ingested) to the human body without being degraded and/or 
denatured by the digestive tract and/or liver.1,4,28,29 Traditionally, these types of 
biologics are administered to subjects as injectables; however, there exist certain  
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situations or conditions in which injection of biologics is not feasible or preferred, 
including drug delivery on the battlefield and in biological warfare. By having such 
therapies in a readily consumable and easily transportable format, soldiers will be 
better prepared to respond to pathogen exposure thereby minimizing the spread of 
illness and death from deadly biological warfare agents such as anthrax, nerve agents, 
smallpox, and Ebola. On a broader scale, patients taking biologics or drugs for ailments 
such as cancer and autoimmune diseases will benefit from alternatives to intravenous 
injections.1,4,28,29 
Octreotide Acetate 
An FDA advisor to SEP Technologies suggested octreotide acetate as a first candidate 
for clinical testing because it is a positively charged, hydrophilic molecule that is likely 
to have low baseline bioavailability and because pilot data on octreotide suggests that it 
will be useful for clinical trial planning. Octreotide acetate is an octapeptide analogue 
of the hormone somatostatin.7 It is more stable in the body than the natural hormone, 
and consequently has a longer half-life in the body than somatostatin,32 rendering 
octreotide more clinically relevant than naturally occurring somatostatin. Though 
octreotide was initially developed to treat carcinoid tumors and VIPomas15 (vasoactive 
intestinal peptide-omas; a rare endocrine tumor, usually originating in the pancreas), it 
has been found to be capable of modulating gastrointestinal functions by reducing 
gastric acid secretion, delaying stomach emptying, and slowing intestinal motility,24 
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which is beneficial in treating side effects of chemotherapy in cancer patients. 
Octreotide is currently approved by the FDA to treat acromegaly (a syndrome that 
results when the anterior pituitary produces excess growth hormone after puberty), 
flushing (redness of the face) and diarrhea in patients with carcinoid syndrome and 
VIPomas. 
Initial dosage of octreotide in patients with diarrhea associated with chemotherapy is 
100-150 mcg every eight hours subcutaneously.9,23 For severe diarrhea, this may be 
increased to 500-1500 mcg intravenously or subcutaneously every eight hours.23 
Complicated cases may require an initial dosage of 100-150 mcg three times per day or 
an I.V. infusion of 25-50 mcg/hour; this may be increased to 500 mcg three times per 
day until controlled.9 
When octreotide is administered subcutaneously in humans, it reaches its peak plasma 
concentration within 30 minutes. Plasma concentrations are dose-dependent and linear. 
Octreotide, when administered parentally, has an absolute bioavailability of 
approximately 100% and a half-life of approximately 1.7 - 1.9 hours in patients with a 
healthy liver and kidneys.24 When a 100 mcg dose of octreotide is administered in 
humans, a peak plasma concentration of 5.2 ng/ml is reached in approximately 25 
minutes (Clinical Pharmacology Online Database). 
Due to poor oral bioavailability, octreotide must be delivered parenterally. This 
characteristic, in conjunction with the fact that it is typically administered to patients in 
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a chronic manner, makes it an ideal candidate for potential orotransmucosal drug 
delivery. Because octreotide is a relatively small peptide made up of eight amino acids 
and has a positive charge in saliva, it is a good candidate to test whether systemic 
peptide delivery across the oral mucosa can be enhanced by electronic stimulation. 
1.2 Challenges of Systemic Protein and Peptide Delivery 
Successful therapeutic utilization of peptides and proteins depends on the ability to 
administer them in an efficient and patient-compliant manner. Oral delivery (ingestion) 
of peptides and proteins is rarely feasible due to their enzymatic and acidic instability 
in the gastrointestinal tract, as well as their pre-systemic hepatic metabolism (first-pass 
phenomena).27 (Lee and Yamamoto, 1990). Consequently, constituents not suitable to 
ingestion are typically delivered systemically via parenteral routes of administration 
(e.g., subcutaneous, intravenous, or intramuscular injection). Research efforts have 
been directed towards exploring alternate delivery routes for peptide- and protein-based 
pharmaceuticals to increase patient safety and compliance2, as well as address transport 
and storage logistics associated with injectable pharmaceuticals (liquids). Potential 
alternate routes of systemic protein and/or peptide administration include transdermal, 
nasal, orotransmucosal, ocular, rectal, and vaginal, all of which bypass potential 
digestion in the gastrointestinal tract and clearance by the liver prior to reaching 
systemic circulation.6 
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1.3 Transport and Storage Advantages 
Another benefit to administering drugs and biologics via the oral mucosa is that the 
drug/biologic can be transported, stored, and administered in its solid form. Drugs and 
biologics in liquid form (injectables) are unstable and challenging to store and transport 
since variables such as temperature and light exposure must be taken into account. By 
administering drugs orally, the solid form of the drug can be utilized since the saliva 
dissolves the drug into a suspension at the time of drug administration. 
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2. OVERVIEW OF TRANSEPITHELIAL DRUG DELIVERY 
Sublingual administration is a type of transepithelial drug delivery. This section is a 
review of the literature for this route of drug administration. 
2.1 Transdermal Drug Delivery 
The skin is made up of the epidermis and the dermis, which forms the cutis. Located 
above the dermis, the epidermis consists of a stratified squamous epithelium and, on 
average in humans, measures approximately 40-50 microns in thickness, but varies 
greatly between subjects, location on the body, age, and gender.41 The epidermis 
consists of five distinct zones of cells in varying degrees of differentiation. Located 
right above the basal lamina is the stratum basale, which is made up of mitotically 
active cells. After division, these epithelial cells begin to differentiate and migrate 
towards the skin’s surface, becoming a part of the stratum spinosum, stratum 
granulosum, stratum lucidum, and eventually the stratum corneum (Fig. 1), which is 
located at the skin’s surface.10  
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The barrier properties of skin lie mostly in this uppermost layer, the stratum corneum,34 
which consists of differentiated, lamellar, non-nucleated (keratinized) cells or 
corneocytes which are filled with keratins and embedded in a lipid domain. This layer 
is considered to be the rate-limiting step for skin absorption of most molecules.17 The 
stratum corneum is approximately 8-13 microns thick in humans and is made up of 
about 15-23 cell layers, which varies between individuals and sample location.20 
Stratum corneum thickness and rate of transdermal diffusion are inversely related.20 
The stratum corneum, along with the rest of the epidermis, allows some 
Figure 1: Skin Epithelium Structure. From 
Wikipedia (public content) 
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pharmaceuticals (particularly lipophilic particles) to pass via passive intercellular 
diffusion amongst the extracellular lipids.10 
There are a few pharmaceuticals that are well-suited to transdermal drug delivery; 
however, since there are many specific parameters that make a drug conducive to this 
route of systemic delivery - including aqueous solubility, lipophilicity, molecular 
weight, melting point, pH, and therapeutic dose - there remains a large pool of drugs 
for which transepithelial delivery is desirable, but presently unfeasible due to the 
excellent barrier properties of the stratum corneum.31 
2.2 Transmucosal Drug Delivery 
Transmucosal routes of drug delivery include intraoral, nasal, ocular, rectal, and 
vaginal. Nasal and intraoral routes of administration are the most accepted by the 
patient; however, prolonged use of the nasal route may cause damage to the mucosal 
cilia. Orotransmucosal drug delivery is thought to be the least damaging to the local 
epithelia, while having the highest patient compliance.37 The orotransmucosal route is 
the drug delivery method examined in these studies. 
2.3 Orotransmucosal Drug Delivery 
Systemic drug delivery via the intraoral membranes would address issues with pre-
systemic metabolism both in the gastrointestinal tract and the liver27 while overcoming 
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barrier issues encountered by transdermal drug delivery. Regions in the oral cavity 
where pharmaceuticals can be effectively administered (both locally and systemically) 
are buccal, sublingual, palatal, and gingival. Of these, the buccal and sublingual routes 
are the most commonly used due to physical properties which make them more 
amenable to transmucosal drug delivery.26 Both surfaces are composed of stratified 
squamous non-keritinized epithelia, meaning they lack the barrier layer (stratum 
corneum) encountered in skin. The sublingual mucosa is thinner and more permeable 
than the buccal mucosa, making it ideal for quick delivery of pharmaceuticals.26 Other 
advantages of orotransmucosal drug delivery include ease of access, low enzymatic 
activity, and tolerance to absorption enhancers.27  
One challenge encountered with sublingual drug delivery is effectively keeping the 
dosage in contact with the mucosa due to constant washing by saliva and tongue 
activity.26 A sublingual device, such as the Sublingual Electronic Pill, can help to 
alleviate this problem since the device presses the pharmaceutical agent against the 
sublingual mucosa through the downward action of the patient’s tongue on the device. 
To be successfully delivered transmucosally, substances must have a proper balance 
between aqueous solubility and lipophilicity. Even drugs that are well-suited to 
transmucosal drug delivery can only be delivered a few milligrams at a time.26 Studies 
have shown that the main permeation barrier is membrane coating granules (MCGs), 
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which are found in keratinized and non-keratinized epithelia.26 The components of 
MCGs differ between keratinized and non-keratinized epithelia.26  
There are three very distinct and necessary phases of substance diffusion across the oral 
epithelium. First, the compound must dissolve and disperse into the saliva. It must then 
cross the unstirred water layer consisting of a mucin network at the epithelial surface, 
and lastly, the drug crosses the oral mucosa.23 Often, the aid of absorption enhancers is 
needed to achieve a systemic therapeutic level of larger hydrophilic peptides.23,35 For 
smaller lipophilic peptides, dissolution enhancers are often needed to achieve the 
aforementioned first phase of substance diffusion across the oral mucosa.23  
Some peptides and proteins are readily absorbed across the oral mucosa via passive 
paracellular diffusion; however, as compared to injection, transmucosal drug delivery 
to the systemic blood stream is vastly less efficient.37 In order to efficiently utilize this 
convenient route of systemic drug delivery, the potential systemic bioavailability of the 
administered drug must be improved upon. Bioavailability of drugs administered 
sublingually has been moderately increased versus diffusion alone by utilizing various 
bioadhesion-enhancing molecules;37 however, bioavailability still remains vastly 
substandard as compared to parenteral routes of administration.37  
Preliminary unpublished research by SEP Technologies has shown that low-level 
electronic stimulation of the sublingual mucosa causes an increase in blood flow and an 
increased porosity in the mucosal tissues (SEP Technologies, Inc. DARPA grant 
11 
 
 
 
proposal). Hence, transmucosal electrical stimulation may provide a convenient and 
effective manner by which to increase systemic peptide bioavailability via 
transmucosal diffusion in a way that is therapeutically significant. 
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3. OVERVIEW OF ELECTRICAL STIMULATION IN MEDICINE AND 
MEDICAL DEVICES 
Electrical stimulation of oral mucosa to increase absorption of bioactive agents is a 
recent use of electricity in medical devices. This section is a review of electrical 
stimulation devices.  
3.1 Transdermal Electrical Stimulation 
The earliest use of transdermal electrical current appears to be about 5000 years ago.33 
Greek and Roman physicians utilized electric fish capable of generating 100-150 volts 
of electricity applied to the skin for the treatment of ailments such as headache, 
arthritis, and hemorrhoids.33 Although electricity has been used over the centuries to 
cure a variety of ailments, the modern era of utilization of electricity in medical 
applications did not begin until the nineteenth century, by which time most American 
physicians possessed at least one electrotherapeutic machine.33 
Today, therapeutic and diagnostic applications of electrical stimulation in medicine are 
widespread.33 Amongst the extensive usages of electricity in medicine, application of 
an electric current to skin has been found to be beneficial in transdermal drug delivery, 
primarily in the form of iontophoresis.5,12,22,33,38,39,40 Iontophoresis is defined as a 
facilitated movement of charged compounds into or across a membrane in the presence 
of an externally applied electrical potential across the membrane.21 While iontophoretic 
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applications usually employ a direct DC current, pulsed DC waveforms and alternating 
currents are occasionally utilized.12 
The mechanisms underlying electrically-induced changes in the skin’s electrical 
properties are not fully understood. Applying a current may alter the skin’s ion 
concentration, decreasing the skin’s resistance.33 Electric field-induced electroosmosis 
may also play a role in the skin’s decreased resistance in the presence of an electric 
current.33 This reduction in skin resistance is often related to an increase in skin 
permeability.33 This decrease in skin resistance may be explained by the reorientation 
of lipid structures within the epithelium during electrical stimulation since skin lipids 
are a significant barrier to transdermal ion transport.33 
Electroporation, which is usually caused by a short (10 µs to 10 ms), high-voltage 
(transmembrane voltage of ~1 v) electric field pulse, may be involved in the creation of 
transient aqueous pathways in lipid bilayers, resulting in structural changes in stratum 
corneum lipids.33 Electroporation has been found to reversibly increase permeability in 
both metabolically inactive systems (e.g., liposomes) and in living cells by many orders 
of magnitude.  The reduction in resistance in the epithelium seen at low voltages and 
without any changes in skin structure may be explained by a mechanism involving 
convective transport by electroosmosis.18,33 
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In general, iontophoretic increases in diffusion of charged compounds across a 
membrane is thought to act primarily by electroosmosis and electrorepulsion, which 
occurs when an electric field repels compounds of like charges.18,21,30  
3.2 Orotransmucosal Electrical Stimulation 
Iontophoretic applications in the oral mucosa are relatively novel and still require 
additional investigation to better understand the underlying mechanisms of action and 
to maximize efficiency. Buccal and sublingual drug delivery has seen several advances 
in the last 5 years,36 with a favorable outlook on the future of potential buccal and 
sublingual delivery systems.36 It is also expected that physical means of enhancing 
orotransmucosal drug delivery, such as sonophoresis, iontophoresis, and 
electroporation, will be commercialized for buccal drug delivery.36 According to Senel, 
buccal and sublingual delivery, in general, is attractive for the development of 
intellectual property. 
Most studies on the effects of iontophoresis in the oral mucosa have been performed on 
the buccal mucosa; electroosmotic effects, electrorepulsion effects, and a decrease in 
mucosal resistance over time have been demonstrated  in excised pig cheek; however, 
these results are local in nature (versus systemic).14,16,21,30  
In Europe, animal studies have shown success of buccal transmocusal delivery of 
naltrexone in pigs capable of delivering therapeutic plasma levels of drug while 
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avoiding spikes in blood levels associated with IV delivery.11 This research is being 
conducted in the development of a buccal transmucosal drug delivery device, called 
“IntelliDrug”. However, the “IntelliDrug” device can only be utilized in patients who 
are missing two side-by-side molars due to device size and placement.13,35 
Additionally, peptide drugs cannot diffuse across the oral mucosa unaided; therefore, 
studying the effects of iontophoretic delivery on such molecules would be significant in 
the development of iontophoretic orotransmucosal technologies.13 
Considering the mechanisms referenced in Section 3.1 and the unpublished study by 
SEP, Inc. (mentioned in Section 2.3), we believe that the application of an electrical 
stimulus across the sublingual mucosa may result in an increase in the sublingual 
delivery of octreotide acetate into systemic circulation. This may occur due to one or 
multiple mechanisms associated with epithelial electrical stimulation within the range 
of applied currents (approximately 7 mA) and waveforms (20 Hz square wave [T=5 
ms] and direct current) associated with our experimental setup, including: an increase 
in local capillary blood flow; a reduction in epithelial resistance; an increase in 
epithelial permeability; and an increase in ion (electrorepulsion) and water movement 
(electroosmosis) in the mucosa. 
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4. DEVELOPMENT OF AN ELECTRICAL SYSTEM TO DELIVER LOW-
CURRENT DC AND AC STIMULI TO THE ORAL MUCOSA OF 
RABBITS 
Electrical stimulation is thought to act in two ways to increase drug absorption across 
the mucous membrane: 1) via a net electrical field (DC current) across the mucous 
membrane to increase diffusion of a charged molecular drug entity across the 
membrane, and 2) via alternating current stimulation to open up capillaries and cellular 
pores and thus increase absorption into the blood stream (correspondence with Yossi 
Gross, founder of SEP Technologies, Inc.). Our study was designed in such a way that 
both components will be tested individually. 
4.1 System Requirements 
In order to test the hypothesis that electrical stimulation increases systemic 
bioavailability of octreotide via sublingual transmucosal delivery versus diffusion 
alone, a system with which to deliver and measure an electrical stimulus across the oral 
mucosa of rabbits needed to be conceptualized and fabricated. Specifications of this 
system included capabilities of delivering a known current and waveform to the test 
subject in a reliable manner when a known voltage/waveform is input into the system.  
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We planned to deliver a direct current of +8 mA and -8 mA to Direct Current Test 
Subjects and a square wave of 8 mA peak-to-peak at a frequency of 20 Hz to 
Alternating Current Test Subjects. These parameters were chosen based on preliminary 
unpublished studies by SEP Technologies, Inc. that show that this amount of current 
and frequency are typically low enough to be safe to patients while still delivering a 
therapeutic level of electrical stimulation. The system also needed to be adjustable on 
the order of tenths of a volt since we were not certain how test subjects would react to 
electrical stimulation. The system also needed to possess the capability to cease 
stimulation at any time should a test subject react adversely (defined by exaggerated 
muscle twitching and/or muscle tetany, or other adverse unforeseen reactions). The 
system was also required to be portable since it needed to be transported between 
facilities/test subjects. The system needed to have capabilities to measure, record, and 
verify input waveforms/voltages and the waveforms/currents across the test subject. 
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4.2 System Construction 
A voltage-controlled current source was chosen to be part our electrical stimulation 
device (Fig. 2). This circuit allowed us to input a known voltage into the circuit and 
provide a voltage to the test load that is proportional to the input. This circuit allowed 
the user to set and adjust this gain between the input current and the current across the 
test subject depending on which resistor values were chosen in our circuit – we chose 
to construct this circuit with a gain of 1 (i.e., input voltage is equal to the voltage across 
the test load) by leaving RG open (or infinite resistance) and by choosing resistors for 
the circuit based on an assume load resistance of 1kΩ since this has been found to be a 
good estimate of the resistance of wet skin.33 We utilized an AD620 instrumental 
amplifier3 which is low-cost, low-power, highly accurate, and capable of providing a 
precision current source when implemented in conjunction with an LM741 operational 
amplifier, resistors, an input power source, and am amplifier power source. This circuit 
and components were chosen after consideration of our desired output currents and 
frequency, and consultants in the TAMU Physics Department Electronics Shop 
recommended it as a very precise and reliable circuit with which to deliver a constant 
low-current stimulation to test subjects. 
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Our stimulation system consisted of a power source, the aforementioned precision 
current source, a function generator, and an oscilloscope, along with basic electrical 
components (wires, resistors, BNC adaptors, alligator clips, etc.; Fig. 3). The output pin 
of the circuit was attached via alligator clips to the oral electrode (Fig. 4) which would 
be inserted around the tongue of the test subjects. The function generator was utilized 
to input specified voltages and waveforms into the circuit (e.g., +8 V, -8 V, and a 20 
Hz square wave 8 V peak-to-peak) to elicit the desired currents and waveforms across 
the oral mucosa of the test subjects (e.g., +8 mA, -8 mA, 20 Hz square wave 8 mA 
peak to peak).  
  
 
Figure 2: Voltage-Controlled Current Source Schematic. 
Voltage-controlled current source schematic utilizing an AD620 
instrumental amplifier in conjunction with an LM741 operational 
amplifier. From the AD620 Datasheet PDF3 
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Figure 4: Oral Electrode. Oral electrode constructed out of stainless steel 
suture; circular portion to be positioned around the tongue of the test subject, 
straight end attached to output pin of the precision current source via 
alligator clip. 
 
Figure 3: Electrical Stimulation System Set Up. Electrical stimulation system to deliver low-
current AC and DC stimuli to the oral mucosa of rabbits. Top left: function generator to generate 
input waveform into the precision current source circuit; Top right: Oscilloscope to measure 
waveform actually delivered to test subject; Lower left: precision current source circuit. 
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The system was first tested using a 1 kΩ resistor as a test load to determine 
approximate voltage input ranges for the test subjects, as well as to verify desired 
output currents (Fig. 5). We also tested the system with increasing test loads (0.5 kΩ - 
8 kΩ) to verify the range of resistances in which the system behaved as desired. From 
this, we found that the system was capable of delivering an output current (4 mA) that 
was proportional to the input voltage (4 v) up to a load resistance of approximately 3.5 
– 4 kΩ (Fig. 6).  
 
Figure 5: Oscilloscope Reading on Test Load. AC Square Wave (20 Hz) oscilloscope reading for 
a test resistance of 1 kΩ. 
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The oscilloscope was used to visualize the input voltages and waveforms from the 
function generator, as well as the output currents and waveforms across the test load 
and/or test subject in real time to verify that the proper electrical stimulation was 
delivered to the test subjects. 
  
Figure 6: Precision Current Source Load Resistance vs. Voltage. Test load resistance vs load 
voltage. Circuit is able to deliver desired currents to load resistances up to approximately  3.5 – 4 
kΩ. Rabbits are expected to have a resistance between 1-2 kΩ. 
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4.3 System Limitations 
We did not know our actual load resistance (rabbit mucosa) until we utilized the device 
on the animal; therefore, we had to construct the electrical circuit based on an estimated 
test load resistance. Additionally, a resistor alone is not an accurate representation of 
the impedance of the test subject due to the body’s capacitive characteristics; however, 
it was determined to be within an acceptable tolerance for this experiment. 
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5. EXPERIMENTAL PROTOCOL TO TEST EFFICACY OF SUBLINGUAL 
DRUG DELIVERY UTILIZING LOW-CURRENT DC AND AC STIMULI 
TO THE ORAL MUCOSA OF RABBITS 
All animal experiments were performed under an Animal Use Protocol (AUP) 
approved by the Texas A&M University Institutional Animal Care and Use Committee 
(IACUC). Twenty-five specific pathogen free (SPF) female New Zealand White 
(NZW) rabbits were purchased from Harlan Laboratories for this study. They were 
housed in the Texas A&M University central vivarium, which is a part of the 
institutional accreditation by the Association for the Assessment and Accreditation of 
Laboratory Animal Care, International (AAALAC) under conditions that met standards 
of the Guide for the Care and Use of Laboratory Animals, as well as those set by the 
United States Department of Agriculture. The light cycle was 12:12, and animals were 
provided with enrichment through the use of novel toys, supplemental hay, and 
frequent handling by the care staff. Eight ounces of laboratory grade feed (Harland 
Laboratories) was provided daily, and water was provided ad libitum. 
5.1 Test Animal Study 
Prior to the commencement of the drug absorption study, a test run was conducted on 
one anesthetized test subject (NZW rabbit) obtained through the Texas A&M 
University Laboratory Animal Resources and Research Facility (LARR) in order to 
ensure proper device setup and function, as well as to ascertain how the animal would 
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tolerate electrical stimulation. This study was beneficial to test system operation on a 
live subject, discern ideal electrode configuration and placement, and to find the best 
placement for the animal during the study. 
The animal was anesthetized with a combination of ketamine, xylazine, and 
acepromazine (35 mg/kg ketamine, 5 mg/kg xylazine and 0.75 mg/kg acepromazine) 
administered intramuscularly (IM). The appropriate depth of anesthesia was confirmed 
prior to the commencement of the study by use of a toe pinch reflex. The animal was 
intubated with an endotracheal tube which was left open for non-assisted breathing and 
placed on its left side. Intubation was performed to keep the orally administered 
octreotide from being aspirated and/or dripping down the esophagus. Gauze was 
utilized to secure the endotracheal tube, and the animal’s head was propped up with a 
small towel at an angle of approximately 15 degrees. The stainless steel wire electrode 
loop was placed around the tongue and attached to the output pin of the precision 
current source. Aluminum cardiac pacing wire was placed subcutaneously in the 
animal’s right thigh and attached to the circuit ground. 
The electrical system was then turned on, beginning at 0 volts direct current. We 
incrementally increased/decreased the input signal in tenths of a volt until we reached 
+/-8 mA across the test subject. During the early stages of this pilot experiment, it was 
discovered that the disparity in the thigh and oral electrode materials was causing a DC 
offset, and consequently the thigh electrode was replaced with the same stainless steel 
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as the oral electrode. Additionally, we tested alternating square wave tolerance at 20 
Hertz (Hz), again beginning at 0 mA peak-to-peak and incrementally increasing by a 
tenth of a mA until twitching was observed. This occurred around 5 mA peak-to-peak 
current across the rabbit. From this initial test study we determined that the 
approximate impedance of the oral mucosa of the rabbit was 1.2 kΩ (measured with a 
multimeter), and that the target direct current stimulus to test subjects would be 
between +/-4 mA, while the target alternating current would be approximately 4 mA 
peak-to-peak.  
Administration of octreotide acetate to the oral cavity of the animal was performed 
until we were able to deliver the drug from the syringe at a constant rate of 1 
ml/minute.  
Upon completion of the test study, the animal was euthanized in accordance with an 
approved Facility Use Protocol with an overdose of a barbiturate. 
5.2 Octroetide Absorption Study Protocol 
The industrial partner for this project, SEP Technologies, has performed preliminary 
unpublished experiments that show that electrical stimulation may act in two ways to 
increase octreotide diffusion across the mucous membrane: 1) via a net electrical field 
(DC current) across the mucous membrane to increase diffusion of a charged molecular 
drug entity across the membrane, and 2) via alternating current stimulation to open up 
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capillaries and pores, as well as increase local blood flow, and thus increase absorption 
into the blood stream.  
We utilized twenty five SPF NZW rabbits from the same lot, of similar weights (and 
hence similar blood volumes), and of the same sex (females) obtained from Harlan 
Laboratories in order to effectively compare octreotide serum concentrations and limit 
variances between test subjects. Syringes of octreotide acetate were obtained from 
Sigma-Aldrich® and stored in the refrigerator at LARR. All octreotide was from lot 
AL11007 and expires on 1/2013. 
Each rabbit was randomly assigned a number (R41-R65) in order to blind the personnel 
performing the serum octreotide concentration analysis, and experiments were 
performed in a randomly selected order. Five groups of five subjects were tested to 
determine feasibility of the SEP technology using a small, charged peptide that is 
relatively non-absorbable across the mucosa without stimulation. Each test group 
consisted of five test subjects, and included: 
a) Subcutaneous Control Group (Control) – to establish a benchmark or gold 
standard for octreotide absorption into the blood stream; each SubQ animal 
received a bolus injection of 1 ml of 50 mcg/ml octreotide for a total dosage of 
50 mcg. 
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b) Baseline Oral Absorption Control Group (Sham) – to establish a baseline blood 
concentration of octreotide absorption across the oral mucosa in the absence of 
electrical stimulation; serum octreotide concentrations of the stimulated groups 
will be compared against this group to establish statistical significance of 
electrical stimuli on sublingual octreotide absorption. Each animal in this group 
received an oral drip for the duration of stimulation at a rate of 0.1 ml/minute of 
50 mcg/ml octreotide (total 3 mls over 30 minutes, 150 mcg total). 
c) Positive Direct Current (+DC) Stimulation Group – to test how sublingual 
octreotide absorption is enhanced by the application of 4 mA DC stimulus 
across the oral mucosa. Each animal in this group received an oral drip for the 
duration of stimulation at a rate of 0.1 ml/minute of 50 mcg/ml octreotide (total 
3 mls over 30 minutes, 150 mcg total). 
d) Negative Direct Current (-DC) Stimulation Group – to test how absorption is 
enhanced by the application of a negative 4 mA DC stimulus across the oral 
mucosa. Each animal in this group received an oral drip for the duration of 
stimulation at a rate of 0.1 ml/minute of 50 mcg/ml octreotide (total 3 mls over 
30 minutes, 150 mcg total). 
a) Alternating Current (AC) Stimulation Group – to test how absorption is 
enhanced by the application of a 20 Hz alternating current square wave 4 mA 
peak-to-peak stimulus to the oral mucosa. Each animal in this group received an 
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oral drip for the duration of stimulation at a rate of 0.1 ml/minute of 50 mcg/ml 
octreotide (total 3 mls over 30 minutes, 150 mcg total). 
Each rabbit was injected with a combination of ketamine, xylazine, and acepromazine 
(35 mg/kg ketamine, 5 mg/kg xylazine, and 0.75 mg/kg acepromazine injected IM) to 
induce anesthesia ten minutes before the commencement of its respective study. It was 
determined that the experimental duration for each animal would be 30 minutes based 
on expected length of anesthesia following one dose (approximately 45 - 60 minutes). 
If animals showed signs of distress, depth of anesthesia was determined via a toe pinch 
reflex, and if needed re-dosed with a half-dose of anesthesia. Animals were terminated 
immediately upon completion of the experiment with an overdose of the same 
anesthetic utilized to induce anesthesia and disposed of in accordance with the TAMU 
approved AUP. Following euthanasia, tissues were provided to other investigators 
through the TAMU Tissue Sharing Program in order to assure the maximum possible 
use of the animals. 
Subcutaneous Control Group 
After anesthesia was administered and the appropriate depth confirmed via a toe pinch 
reflex, the animal was placed in left lateral recumbency on the operating table and a 
bolus injection of 1 ml of 50 mcg/ml octreotide acetate (total 50 mcg) was administered 
subcutaneously between the shoulder blades at time zero of the study.  
30 
 
 
 
At time zero, 5 minutes, 10 minutes, and 30 minutes 3 ml of blood was drawn with a 
needle and syringe from the auricular artery of the left ear for serum octreotide 
concentration analysis. Alternately, the right ear was used if the left ear artery became 
blocked or constricted. All blood samples were then placed in a serum separator tube 
tube and allowed to clot (Fig. 7), and they were stored in the refrigerator until 
processing later in the same day as the experiment was performed. 
 
  
Figure 7: Serum Separator Tube 
Containing Blood Sample. Serum 
separator tube containing clotted raw 
samples for octreotide testing 
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Electrical Stimulation Groups (Positive DC, Negative DC, and AC stimuli) 
After anesthesia was administered and confirmed utilizing the toe pinch reflex, the 
animal’s right hip was shaved in preparation for the ground electrode placement. The 
animal was intubated to ensure that the oral drip stayed in the oral cavity and did not 
drip down the animal’s esophagus or trachea. The animal was then placed on its left 
side on the operating table with its head propped up with a towel to ensure that the oral 
drip stayed in the oral cavity (Fig. 8). The oral electrode was placed in the oral cavity 
around the tongue, in contact with the sublingual mucosa. The hip electrode was 
inserted subcutaneously with a reverse cutting needle so that it penetrated the skin and 
then exited the skin approximately a half inch from the insertion point. With the 
function generator set to either direct current at zero volts or alternating 20 Hz square 
wave at zero volts peak-to-peak and turned in the “off” position, the oral electrode was 
connected to the output pin of the precision current source, and the thigh electrode was 
connected to ground utilizing alligator clips. The oral cavity was moistened slightly 
immediately prior to commencement of electrical stimulation to ensure similar 
impedance throughout the study (impedance is significantly increased when the mucosa 
is dry).  
32 
 
 
 
At time zero, the function generator was switched to the “on” position and 
increased/decreased to the target current (+/- 4 mA DC, 4 mA peak-to-peak AC), the 
octreotide acetate oral drip (50 mcg/ml) was commenced at a rate of 0.1 ml/minute for 
30 minutes (total volume of 3 mls, total dosage of 150 mcg octreotide), and the time 
zero blood draw was performed (3 ml from the auricular artery in the left ear with a 
needle and syringe, placed in a serum separator tube and allowed to clot). Each animal 
was monitored carefully throughout the duration of the experiment to ensure that no 
muscle tetany or twitching occurred, and the voltage across the mucosa was monitored 
throughout the experiment via the oscilloscope for Rr calculations. Blood draws were 
Figure 8: Animal Set Up. Animals were intubated and 
placed on their left side for the duration of the experiment 
with head propped on a towel to maximize amount of oral 
drip that stayed in contact with the mucosa 
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performed in the same manner as the time zero blood draw at 5 minutes, 10 minutes, 
and 30 minutes for octreotide serum concentration testing. At time=30 minutes, the oral 
drip ceased, and the function generator was switched to the “off” position to halt 
electrical stimulation. The oral electrode was then removed from the oral cavity, and 
the animal was euthanized with an overdose of a barbiturate as approved in the TAMU 
IACUC-approved AUP. Tissue was harvested post-mortem through the TAMU Tissue 
Share program (if there was a need). Termination was confirmed by absence of corneal 
reflex and cessation of heart beat and respiration for at least 5 minutes. Animals were 
disposed of in accordance with our TAMU IACUC-approved AUP.  
Baseline Oral Absorption Control Group (Sham) 
After anesthesia was administered and confirmed utilizing the toe pinch reflex, the 
animal’s right hip was shaved in preparation for the ground electrode placement. The 
animal was intubated to ensure that the oral drip stayed in the oral cavity and did not 
drop down the animal’s throat or into the lungs. The animal was then placed on its left 
side on the operating table with its head propped up with a towel to ensure that the oral 
drip stayed in the oral cavity. The oral electrode was placed in the oral cavity around 
the tongue, in contact with the sublingual mucosa. The hip electrode was inserted 
subcutaneously with a reverse cutting needle, and then exited the skin approximately 
one half inch from the insertion point. The electrodes were not attached to the precision 
current source in this group. 
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At time zero, the octreotide acetate oral drip was commenced at a rate of 0.1 ml/minute 
50 mcg/ml for 30 minutes (total volume of 3 mls, total dosage of 150 mcg), and the 
time zero blood draw was performed (3 ml from the auricular artery in the left ear with 
a needle and syringe) and placed in a serum separator tube and allowed to clot. Blood 
draws were performed in the same manner as the time zero blood draw at 5 minutes, 10 
minutes, and 30 minutes for octreotide serum concentration testing. At time=30 
minutes, the oral drip ceased. The oral electrode was then removed from the oral cavity 
and the animal was euthanized with an overdose of a barbiturate as approved in the 
TAMU IACUC-approved AUP. Tissue was harvested post-mortem through the TAMU 
Tissue Share program (if there was a need). Termination was confirmed with absence 
of corneal reflex and cessation of heart beat and respiration for at least 5 minutes. 
Animals were disposed of in accordance with our TAMU IACUC-approved AUP.   
Blood Sample Preparation for Octreotide Concentration Analysis 
The clotted samples were stored in the refrigerator until centrifugation (Fig. 9). After 
spinning the sample serum was extracted and placed in 1 ml aliquots, each containing 
about 0.5 ml of serum. The serum samples were labeled by rabbit number, blood draw 
time (0, 15, or 30), date acquired, and PI name, then stored in the -20 degrees 
Fahrenheit no-frost freezer until delivery to the radioimmunoassay laboratory. 
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 Experiment Design 
To test the proposed mechanisms of increased octreotide acetate diffusion into systemic 
circulation, we used 5 different experimental groups, each consisting of 5 animals. The 
groups were: 1) subcutaneous injection control group, 2) positive DC stimulus across 
oral mucosa with octreotide drip in oral cavity, 3) negative DC stimulus with octreotide 
drip in oral cavity, 4) alternating square wave with octreotide drip in oral cavity, and 5) 
sham group with octreotide drip in oral cavity to determine the baseline absorption 
across the oral mucosa. The stimulation groups (2-4) were compared to group 5 with no 
stimulation (i.e, sham or baseline sublingual absorption group) to test our hypothesis 
that electrical stimulation will increase the absorption. A control group (injected with a 
1 ml bolus of 50 mcg/ml octreotide at time zero) was also included to compare oral drip 
results with the current gold standard of octreotide administration. The animals were 
randomized into the 5 groups, and the laboratory performing the serum tests was 
blinded. 
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Figure 9: Centrifuge. Clotted samples were centrifuged, then 
serum to be tested for octreotide concentration was extracted and 
stored in the -20 degrees Fahrenheit freezer 
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6. ASSESSMENT OF ORAL LOW-CURRENT DC AND AC STIMULI ON 
SUBLINGUAL DIFFUSION OF OCTREOTIDE INTO THE BLOOD 
STREAM OF RABBITS 
Following the completion of the animal studies the frozen aliquots of serum samples 
were delivered to the Texas A&M University Veterinary Teaching Hospital 
Gastrointestinal Laboratory for radioimmunoassay (RIA) analysis to determine serum 
concentrations of octreotide. These data were then processed and utilized to determine 
the efficacy of DC and AC stimuli on sublingual aborption of octreotide. Upon 
completion of the concentration analysis, statistical significance was determined 
between absorption rates of each stimulation group and the Sham group using a 
Welch’s t-test (a test for statistically significant difference in means of two groups with 
unequal variance). The three hypotheses tested were:  
1) Positive direct current electrical stimulation will increase absorption of 
octreotide so that the mean  serum octreotide concentration of the +DC group 
will be greater than that of the sham group, or +DC group > sham, and 
similarly: 
2) –DC group > sham and  
3) AC group > sham  
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Given that the hypotheses are only one-sided (i.e., only the “greater than” side is 
considered), a one-sided Welch’s t-test was used and a p-value of less than 0.05 was 
considered to be significant. If electrical stimulation was indeed successful in 
improving the systemic concentration of octreotide, each electrical stimulation group 
was compared to determine which stimulation scenario rendered the most successful 
results.  
This pilot study was designed solely to discern whether or not electrical stimulation 
increased sublingual diffusion of octreotide into the circulation, and was not designed 
to establish therapeutic significance of sublingual diffusion. However, serum octreotide 
concentrations for sublingual diffusion groups (+DC Stim, -DC Stim, AC Stim, and 
Baseline Oral Absorption Groups) were compared to serum octreotide concentrations 
in the Subcutaneous Injection Group and to typical known therapeutic plasma 
concentrations in humans to determine how sublingual diffusion compared to 
therapeutically significant serum concentrations (the current “gold standard” for 
octreotide administration). 
6.1 Radioimmunoassay Analysis 
Radioimmunoassay analysis was performed by Stephen Lagutchik, a technician in the 
Gastrointestinal Lab at the Veterinary Medicine Teaching Hospital at Texas A&M 
University. First, the samples were purified, and the octreotide was extracted using S-
5000 extraction Kits purchased from Peninsula Laboratories. Once the octreotide 
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(primary antibody) was extracted, an RIA buffer, antiserum, a radioactive tracer, and a 
secondary antibody were added utilizing a rabbit octreotide RIA kit from Bachem (S-
2217 Octreotide RIA kit). This kit has a typical sensitivity of 0.17 ng/ml and a range of 
0.010 – 1.28 ng/ml. The known concentration of tracer competes with the unknown 
concentration of antigen (octreotide) in the sample for binding sites on the antiserum. 
Immunocomplexes were precipitated by adding normal serum and secondary 
antibodies followed by centrifugation. The unbound reagents were decanted, leaving 
the radioactive pellet behind. The pellet was counted on the gammacounter, which 
measures the radioactivity of the pellet in counts per minute (cpm). The more antigen 
(octreotide) that binds to the antiserum, the less the tracer is bound, so a higher 
concentration of antigen (octreotide) correlates to a lower cpm. Using the cpm results 
for each tube from the gammacounter, the octreotide concentrations for each rabbit at 
each time point were calculated for each sublingual group. 
6.2 Results 
Sublingual Diffusion Serum Octreotide Concentration Analysis 
Octreotide serum concentration tables were generated containing rabbit number, the 
date the experiment was performed, voltage input into the circuit (Vin), the voltage 
recorded across the animal during the experiments utilizing the oscilloscope (Vr; Figs. 
10 and 11), the known current across the animal (Ir; Ir (mA) = Vin (v)), the calculated 
resistance value of each animal (Rr; Rr = Vr/Ir), and serum concentrations  
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Figure 10: +DC Vr Oscilloscope Image. +DC voltage measured across R46 
Figure 11: AC Vr Oscilloscope Image. AC voltage measured across R50. Signal is not a 
perfect square wave due to capacitance properties of the rabbit not accounted for in circuit 
design. 
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for each sublingual diffusion group (Tables 1-4). Octreotide serum concentration data 
over time are displayed as a line plot and contains concentration values for each rabbit 
at each time point (blood draw), as well as the average concentration for that group 
(Figs. 12 - 15). For one animal in each stimulation group, the voltage across the animal 
was observed multiple times and recorded for Rr calculations. For the Positive DC 
Stimulation Group, the Ir for all rabbits was 4 mA and the average Rr was 1.8 kΩ. For 
the Negative DC Stimulation Group, the Ir for all rabbits was -4 mA and the average Ir 
was 1.7 kΩ. For the AC Stimulation Group, the average Ir was 2.3 mA peak-to-peak 
and the average Ir was 1.4 kΩ. Note that the target current for AC became 2 mA peak-
to-peak when R50 displayed twitching at both 4 mA peak-to-peak and 3 mA peak-to-
peak. 
A single-sided Welch’s t-test was performed to determine statistical significance of 
serum octreotide concentration at t=30 for each stimulated group (compared to serum 
octreotide concentrations at t=30 in the Baseline Oral Absorption group). A p value of 
less than 0.05 was our indicator for statistical significance. Each stimulated group was 
compared to the Oral Baseline Absorption Group to determine how/if stimulation 
increased serum octreotide concentration, and p values were calculated for each to 
determine statistical significance of the effects of electrical stimulus on serum 
octreotide concentrations.  
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The maximum octreotide serum concentration for the Baseline Oral Absorption Group 
at 30 minutes was R48 with a concentration of 0.17 ng/ml, and the mean at 30 minutes 
was 0.074 ng/ml.  We found that after 30 minutes of stimulation, +DC stimulation 
produced an average serum octreotide concentration that was nine times greater than 
the Baseline Oral Absorption group (max was in R51 with a concentration of 1.33 
ng/ml, and mean is 0.677 ng/ml.), and was found to be statistically significant with a p 
value of 0.023. The Negative DC Stimulation group had an average serum octreotide 
concentration that was seven times greater than the Baseline Oral Absorption group 
after 30 minutes of exposure to oral octreotide (max was in R49 with a concentration of 
1.575 ng/ml, and mean was 0.535 ng/ml.), but could not be confirmed as statistically 
significant with a p value of 0.08. The AC Stimulation group had an average octreotide 
serum concentration at t=30 minutes that was 3 times greater than the average 
octreotide serum concentration of the Baseline Oral Absorption group at t=30 minutes 
(max was in R61 with a concentration of 0.65 ng/ml, and mean was 0.253 ng/ml), but 
was not statistically significant with a p value of 0.09. Average octreotide 
concentrations for each sublingual diffusion group (+DC Stim, -DC Stim, AC Stim, 
and Baseline Absorption) are displayed as a line plot for more clear comparison 
between sublingual diffusion groups (Fig. 16). 
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Rabbit number, experiment date, animal  weights, input voltage (zero for all since this group received 
no stimulation), and serum octreotide concentrations. This group was used as a baseline to determine 
statistical significance of serum octreotide concentrations in the stimulated groups. 
TABLE 1: Baseline Oral Absorption Group Serum Octreotide Concentration Data (ng/ml) 
 
Figure 12: Baseline Oral Absorption Group Octreotide Serum Concentrations. Baseline Oral 
Absorption group serum octreotide concentrations for each rabbit, as well as the average for the 
group in ng/ml. The max serum concentration at 30 mins is R48 with a concentration of 0.17 ng/ml, 
and the mean at 30 mins is 0.074 ng/ml.  This group was used as a baseline to determine statistical 
significance of serum octreotide concentrations in the stimulated groups. 
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Rabbit number, experiment date, animal  weights, input voltage, measured voltage across the rabbit, 
current across the rabbit, calculated resistance of the rabbit, and serum octreotide concentration for 
each rabbit at each blood draw time point. P value for octreotide serum concentration at 30 minutes 
(as compared to Baseline serum concentration at 30 mins) is 0.023, which is statistically significant. 
TABLE 2: Positive DC Stimulus Group Serum Octreotide Concentration Data (ng/ml) 
 
Figure 13: +DC Stim Serum Octreotide Concentrations. Positive DC Stimulation Group serum 
octreotide concentrations for each rabbit, as well as the average for the group in ng/ml from zero to 
thirty minutes. The max at 30 mins is R51 with a concentration of 1.33 ng/ml, and the mean at 30 
mins is 0.677 ng/ml. When compared to Baseline concnetrations at 30 minutes, P value for octreotide 
serum concentration at 30 minutes is 0.023, which is statistically significant. 
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TABLE 3: Negative DC Stimulus Group Serum Octreotide Concentration Data (ng/ml) 
 
Rabbit number, experiment date, animal  weights, input voltage, measured voltage across the rabbit, 
current across the rabbit, calculated resistance of the rabbit, and serum octreotide concentration for 
each rabbit at each blood draw time point. When compared to Baseline concnetrations at 30 minutes, 
P value for octreotide serum concentration at 30 minutes is 0.085, which is not statistically 
significant. 
Figure 14: -DC Stim Serum Octreotide Concentrations. Negative DC Stimulation Group serum 
octreotide concentrations for each rabbit, as well as the average for the group in ng/ml from zero to 
thirty minutes. The max at 30 mins is R49 with a concentration of 1.575 ng/ml, and the mean at 30 
mins is 0.535 ng/ml. When compared to Baseline concnetrations at 30 minutes, P value for octreotide 
serum concentration at 30 minutes is 0.085, which is not statistically significant. 
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TABLE 4: AC Stimulus Group Serum Octreotide Concentration Data (ng/ml) 
 
Rabbit number, experiment date, animal weights, input voltage, measured voltage across the rabbit, 
calculated current across the rabbit, and serum octreotide concentration for each rabbit at each blood 
draw time point. When compared to Baseline concnetrations at 30 minutes, P value for octreotide 
serum concentration at 30 minutes is 0.091, which is not statistically significant. 
Figure 15: AC Stim Serum Octreotide Concentrations. AC Stimulation Group serum octreotide 
concentrations for each rabbit, as well as the average for the group in ng/ml from zero to thirty 
minutes. The max at 30 mins is R61 with a concentration of 0.65 ng/ml, and the mean at 30 mins is 
0.253 ng/ml. When compared to Baseline concnetrations at 30 minutes, P value for octreotide serum 
concentration at 30 minutes is 0.091, which is not statistically significant. 
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Figure 16: Average Sublingual Octreotide Serum Concentrations. Average serum octreotide 
concentrations for each sublingual diffusion group with standard deviation. All three stimulated 
groups exhibit higher serum octreotide concentrations than the Baseline Oral Absorption group 
(sublingual diffusion in the absence of electrical stimulation) at 30 mins. The +DC Stim Group 
exhibited the highest serum octreotide concentrations (nine times greater than the Baseline Group at 
30 mins), the –DC Stim group exhibited serum octreotide concentrations greater than the AC Stim 
Group but less than the +DC Stim Group (seven times greater than the Baseline Group at 30 mins), 
and the AC Stim Group exhibited the lowest serum octreotide concentrations of the stimulated groups 
(three times greater than the Baseline Group at 30 mins). * indicates statistical significance. 
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Sublingual Diffusion Octreotide Absorption Rate Analysis 
Our working hypothesis is that electrical stimulation will increase serum concentration 
of octreotide via an increased rate of absorption. To explicitly test this mechanism of 
action, the time rate of change of octreotide concentration (absorption rate) was also 
calculated for each group to display effect of stimulation on sublingual octreotide 
diffusion. This was done by taking the change in concentration (concentration at t2 – 
concentration at t1) divided by the change in time (t2 – t1), to obtain the average serum 
concentration change per minute between each blood draw over the experimental 
duration. This was calculated for each animal at each Δtime point: between t=0 and t=5 
mins (denoted as d[1]/dt); between t=5 mins and t=10 mins (denoted as d[2]/dt); and 
between t=10 mins and t=30 (denoted as d[3]/dt). These results were then displayed in 
a table and a single-sided Welch’s t-test was performed on each stimulated group to 
determine statistical significance of electrical stimulation on octreotide absorption rate 
as compared to sublingual diffusion in the absence of electrical stimulation (Tables 5-
8). The rate of serum concentration change was also displayed as bar graphs at each 
Δtime to visualize the rate of serum octreotide concentration change for each rabbit at 
each Δtime point (Fig.s 17 - 20). To compare the effects of each electrical stimulation 
scenario on the rate change of sublingual octreotide diffusion, the average rate 
concentration change for each sublingual diffusion group is displayed as well (Fig. 21). 
49 
 
 
 
In the Baseline Oral Absorption Group, the average absorption rate at all Δtime points 
was 0.01 ng/ml/min, with the highest absorption rate occurring in R48 at Δtime point2 
(0.018 ng/ml/min) 
The average octreotide absorption rate of the Positive DC Stimulation group for Δtime 
point1 (0.013 ng/ml/min) was 16 times greater than the rate of Baseline Oral 
Absorption Group at the same Δtime point; for Δtime point2, the +DC average 
absorption rate was 24 times greater than the Baseline group (0.019 ng/ml/min); and at 
Δtime point3, the +DC average absorption rate was 28 times greater than the octreotide 
absorption rate of the Baseline Oral Absorption Group in the same time frame (0.024 
ng/ml/min). The highest absorption rate was seen at Δtime point2 in R51 (0.058 
ng/ml/min). When all concentration rate changes for each rabbit over each Δtime point 
were compared with all rate changes in the Baseline Oral Absorption group, we found 
that +DC absorption rates were statistically significant, with a p value of 0.0008.  
The average octreotide absorption rate of the Negative DC Stimulation group for Δtime 
point1 (0.006 ng/ml/min) was 8 times greater than the rate of the Baseline group at the 
same Δtime point; at Δtime point 2, the –DC group’s average absorption rate (0.025 
ng/ml/min) was 32 times greater than the Baseline group’s average rate change at the 
same Δtime point; and the –DC Stim group’s rate of concentration change at Δtime 
point3 (0.016 ng/ml/min) was 19 times greater than the octreotide absorption rate of the 
Baseline Oral Absorption Group in the same time frame. The highest absorption rate 
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was seen at Δtime point2 in R49 (0.088 ng/ml/min).  When all concentration rate 
changes for each rabbit over each Δtime point were compared with all rate changes in 
the Baseline Oral Absorption group, we found that the -DC Stim Group absorption 
rates were statistically significant, with a p value of 0.032.  
The average octreotide absorption rate of the AC Stimulation group at Δtime point1 
(0.001 ng/ml/min) was 2 times greater than the rate of concentration change of the Oral 
Baseline Absorption group at the same Δtime point; at Δtime point2, the AC Stim 
group’s average absorption rate (0.001 ng/ml/min) was almost equal to the rate of 
concentration change of the Baseline group at the same Δtime point; and the AC Stim 
group’s average absorption rate at Δtime point3 (0.009 ng/ml/min) was ten times 
greater than the octreotide absorption rate of the Baseline Oral Absorption Group at the 
same Δtime. The highest absorption rate was seen at Δtime point 3 in R61 (0.028 
ng/ml/min).  When all concentration rate changes for each rabbit over each Δtime point 
were compared with all rate changes in the Baseline Oral Absorption group, we found 
that the AC Stim Group absorption rates were not statistically significant, with a p 
value 0.135. 
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TABLE 5: Baseline Oral Absorption Group Octreotide Absorption Rates (ng/ml/min) 
Rabbit number, experiment date, animal  weights, input voltage (zero for all since this group received 
no stimulation), and calculated rate of serum octreotide concentration change. This group was used as 
a baseline to determine statistical significance of rate of serum octreotide concentration change in the 
stimulated groups. 
Figure 17: Baseline Oral Absorption Octreotide Absorption Rates. Baseline Oral Absorption 
Group calculated rate of serum octreotide concentration change for each rabbit, as well as the average 
for the group in ng/ml/min for Δtime points 1, 2, and 3. The average at all Δtime points is 0.01 
ng/ml/min, with the highest absorption rate occurring in R48 at Δtime point2 (0.018 ng/ml/min). This 
group was used as a baseline to determine statistical significance of rate of serum octreotide 
concentration change in the stimulated groups. 
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Rabbit number, experiment date, animal  weights, input voltages, measured voltage across the rabbit, 
current across the rabbit, calculated rabbit resistance, and calculated rate changes in serum octreotide 
concentration. P value is 0.0008 over the entire array of calculated rate change in serum octreotide 
concentration values (as compared to the array of calculated rate change in octreotide concentration 
values in the Baseline Absorption Group), which is statistically significant. 
TABLE 6: Positive DC Stimulation Group Octreotide Absorption Rates (ng/ml/min) 
 
Figure 18: +DC Stim Octreotide Absorption Rates. Positive DC Stimulation Group calculated rate 
of serum octreotide concentration change for each rabbit, as well as the average for the group in 
ng/ml/min for Δtime points 1, 2, and 3. Average rate change at each Δtime point is 0.013 ng/ml/min, 
0.019 ng/ml/min, and 0.024 ng/ml/min respectively. Highest absorption rate was seen at Δtime point 
2 in R51 (0.058 ng/ml/min). P value for rate change of octreotide serum concentration over the entire 
array of concentration rate changes is 0.0008 (as compared to the array of calculated rate change in 
octreotide concentration values in the Baseline Absorption Group), which is statistically significant . 
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TABLE 7: Negative DC Stimulation Group Octreotide Absorption Rates (ng/ml/min) 
 
Rabbit number, experiment date, animal  weights, input voltages, measured voltage across the rabbit, 
current across the rabbit, calculated rabbit resistance, and calculated rate changes in serum octreotide 
concentration. P value is 0.032 over the entire array of calculated rate change in serum octreotide 
concentration values (as compared to the array of calculated rate change in serum octreotide 
concentration values in the Baseline Absorption Group), which is statistically significant. 
Figure 19: -DC Stim Octreotide Absorption Rates. Negative DC Stimulation Group calculated 
rate of serum octreotide concentration change for each rabbit, as well as the average for the group in 
ng/ml/min for Δtime points 1, 2, and 3. Average rate change at each Δtime point is 0.006 ng/ml/min, 
0.025 ng/ml/min, and 0.016 ng/ml/min respectively. Highest absorption rate was seen at Δtime point 
2 in R49 (0.088 ng/ml/min).  P value for rate change of octreotide serum concentration over the 
entire array of concentration rate changes is 0.032 (as compared to the array of calculated rate change 
in octreotide concentration values in the Baseline Absorption Group), which is statistically 
significant. 
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TABLE 8: AC Stimulation Group Octreotide Absorption Rates (ng/ml/min) 
 
Rabbit number, experiment date, animal  weights, input voltages, measured voltage across the rabbit, 
current across the rabbit, calculated rabbit resistance, and calculated rate changes in serum octreotide 
concentration. P value is 0.135over the entire array of calculated rate change in serum octreotide 
concentration values (as compared to the array of calculated rate change in serum octreotide 
concentration values in the Baseline Absorption Group), which is not statistically significant. 
Figure 20: AC Stim Octreotide Absorption Rates. AC Stimulation Group calculated rate of serum 
octreotide concentration change for each rabbit, as well as the average for the group in ng/ml/min for 
Δtime points 1, 2, and 3. Average rate change at each Δtime point is 0.001 ng/ml/min, 0.001 
ng/ml/min, and 0.009 ng/ml/min respectively. Highest absorption rate was seen at Δtime point 3 in 
R61 (0.028 ng/ml/min).  P value for rate change of serum octreotide concentration over the entire 
array of concentration rate changes is 0.135 (as compared to the array of calculated rate change in 
octreotide concentration values in the Baseline Absorption Group), which is not statistically 
significant. 
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Figure 21: Average Sublingual Octreotide Absorption Rates. Average calculated rate of serum 
octreotide concentration change for sublingual group in ng/ml/min for Δtime points 1, 2, and 3. At 
Δtime point1, +DC absorption rate is 16x greater than Baseline; -DC absorption rate is 8x more than 
Baseline; and AC absorption rate is 2x greater than Baseline. At Δtime point2, +DC absorption rate is 
24x Baseline; -DC absorption rate is 32x greater than Baseline; and AC absorption rate is equal to 
Baseline. At Δtime point3, +DC absorption rate is 28x greater than Baseline; -DC absorption rate is 
19x greater than Baseline; and AC absorption rate is 11x greater than Baseline. When all rate 
concentration changes at each Δtime point for each rabbit were compared to Baseline, +DC was 
statistically significant, p=0.0008; -DC was statistically significant, p=0.032; AC was not statistically 
significant, p=0.135. * indicates statistical significance. 
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Subcutaneous Serum Octreotide Concentration Analysis 
The intended dosage of octreotide for the subcutaneous group was calculated by taking 
the lower level of therapeutic dosage and serum concentration in humans (100 mcg 
dose, 5.2 ng/ml serum concentration) and dividing by twenty-two. The assumptions 
used in these calculations were based on the fact that rabbit blood volume (BVr) in 
milliliters is approximately 7% of its body weight (BWr) in grams (this parameter is a 
widely accepted estimate of rabbit blood volume; average in our SubQ animals was 
208 ml). Additionally, BVr is approximately twenty times less than that of a human 
(BVh; human blood volume is between 4700 – 5000 ml). The equations used were: 
𝐵𝑉𝑟 =  0.07 ∗ 𝐵𝑊𝑟 
𝐵𝑙𝑜𝑜𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 𝑟𝑎𝑡𝑖𝑜 = 𝐵𝑉ℎ
𝐵𝑉𝑟
= 4700 𝑚𝑙208 𝑚𝑙 = 22 
𝑅𝑎𝑏𝑏𝑖𝑡 𝑑𝑜𝑠𝑎𝑔𝑒 =  𝑇ℎ𝑒𝑟𝑎𝑝𝑒𝑢𝑡𝑖𝑐 𝑑𝑜𝑠𝑒 𝑖𝑛 ℎ𝑢𝑚𝑎𝑛𝑠
𝐵𝑙𝑜𝑜𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 𝑟𝑎𝑡𝑖𝑜 =  100 𝑚𝑐𝑔22 ~ 5 𝑚𝑐𝑔 
Since each syringe of octreotide contained a 50 mcg dose, the volume administered was 
intended to be 0.1 ml to obtain serum octreotide concentrations close to our intended 
concentration of 5.2 ng/ml. However, during the studies, personnel mistakenly 
administered an entire syringe to each subcutaneous subject, which increased the 
dosage by a factor of ten (versus intended dose). 
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Additionally, our original intended dosage would have rendered serum octreotide 
concentrations that exceeded the detection limits of the RIA kit used to detect sample 
octreotide concentrations (this was not discovered until after RIA analysis); therefore, 
with a dosage ten times that of the intended dosage, all subcutaneous animals’ serum 
octreotide concentrations far exceeded levels that we were capable of detecting. For 
this reason, it became necessary to calculate serum octreotide concentrations in each 
subcutaneous animal at 30 minutes. In order to do this, we had to estimate octreotide 
volume of distribution in rabbits. 
This group was originally intended to compare sublingual diffusion groups with a 
known therapeutic serum concentration; however, once we discovered that the animals 
were substantially overdosed, these calculations were used purely to distinguish 
magnitude of disparity between our SubQ group serum concentrations and known 
therapeutic serum octreotide concentrations in humans, as the latter was more relevant 
to determine therapeutic significance in the sublingual diffusion groups. 
To calculate SubQ group serum octreotide concentrations at 30 minutes, first-order 
elimination rate equations were utilized, including: 
𝐶0 =  𝐷𝑜𝑠𝑒𝑉𝑑  
𝑡1/2 =  ln (2)𝑘  
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𝐶𝑡 =  𝐶0 ∗ 𝑒−𝑘𝑡 
where C0 is the original dose, Vd is the volume of distribution, t1/2 is the half-life, k is 
the elimination rate constant, Ct is concentration at time t, and t is time in hours. Half-
life was assumed to be 1.8 hours based on human data, and k was calculated to be 
0.385. Since Vd for octreotide in rabbits could not be found, an estimate was calculated 
using the known Vd in humans (14 L), blood volume in humans (4.85 L), and rabbit 
blood volume by the following equation to render a Vdr of 606 ml for rabbits: 
𝐵𝑉𝑟
𝐵𝑉ℎ
=  𝑉𝑑𝑟
𝑉𝑑ℎ
  
C0 was then calculated by taking our initial dosage (50 mcg) and dividing by our 
calculated Vdr to obtain a value of 82.5 mcg/ml. Both C0 and the calculated elimination 
rate constant were then plugged into the concentration equation with a t=0.5 to obtain 
concentration at time = 30 minutes for each rabbit. These values are shown in Table 9. 
The average SubQ animal serum octreotide concentration was more than 10 times 
greater than therapeutic levels in humans (5.2 ng/ml), and approximately 100 times 
greater than the average concentration in the +DC group (the sublingual group with the 
highest average serum octreotide concentration). 
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Protocol Deviations 
It should be noted that some of the experiments did not follow the protocol exactly due 
to errors/unforeseen variables during the experiment. After reviewing the concentration 
data from these particular animals and recalculating p value data, these deviations did 
not seem to significantly impact the validity of our results. These disparities were 
annotated on each animal’s datasheet, and are as follows:  
  
Experiment date, animal  weights, calculated rabbit blood volume (BVr), volume of distribution 
(Vd), initial concentration (C0), and serum concentrations at 30 mins. This group was intended to be 
used to as a gold standard of therapeutically significant serum octreotide concentrations; however, 
dosage far exceeded therapeutic levels – the average peak plasma concentration of our SubQ groups 
was more than 10 times greater than the lower limit of therapeutic octreotide concentration in 
humans (5.2 ng/ml). Average peak plasma SubQ concentration is approximately 100 times greater 
than serum octreotide concentrations at 30 minutes in the +DC stim group, the sublingual group with 
the highest serum concentrations. 
TABLE 9: Subcutaneous Injection Group Calculated Octreotide Serum Concentrations at 
30 mins (ng/ml) 
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The first four Stimulated animals: Rabbits 42-43 (Positive DC Stimulation Group), 
46 (AC Stimulation Group), and 47 (Negative DC Stimulation Group): 
After completing the first four stimulated animals, it became apparent that we needed 
to increase the gauge of our electrode wire due to oral and hip electrode breakage. All 
four of these animals exhibited lower concentrations of serum octreotide than the 
average and median values in the other animals in their respective groups. Rabbits 42, 
43, and 46 all exhibited the lowest octreotide concentrations in their respective groups 
(Positive DC Stimulation Group and AC Stimulation Group), while Rabbit 47 
exhibited the second-lowest in the Negative DC Stimulation Group. It is possible that 
this smaller gauge of wire was not as effective at delivering the desired current to the 
animals and/or exhibited small fractures that were not observed until the experiment 
was complete (due to observed breakages that occurred with this gauge of wire after 
utilizing for a few experiments). However, two of these animals were in the Positive 
DC Stim group, which still displayed a statistically significant higher concentration of 
serum octreotide than the Baseline Oral Absorption Group. 
Rabbit 46: AC Stimulation Group 
This was the first experiment performed with the animal hooked up to the stimulation 
system, and thus was the operator’s first opportunity to run the system during the 
absorption study. In addition to running the electrical system, the operator was also in 
charge of manually administering the oral octreotide drip and recording relevant times 
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during the duration of the study (start oral drip, start electrical stimulation, blood draws, 
cease oral drip, cease stimulation, etc.), as well as monitoring the voltages recorded on 
the oscilloscope. Due to the operator’s unfamiliarity with performing all duties at once, 
the input voltage was set to 4 v peak-to-peak (which was our target voltage), but the 
frequency was not set, and therefore ran at the default frequency of the function 
generator (100 kHz) for the first 18 minutes of the experiment, after which the 
frequency was decreased to 20 Hz. Additionally, the operator neglected to record the 
voltage across the animal in this experiment; however, due to the other recorded 
voltage data for the AC Stimulation Group animals, it is estimated that the voltage and 
resulting current delivered to the animal was higher than our target of 4 mA (estimated 
at 8 mA based on other animal data). This particular animal did display a noticeably 
lower serum octreotide concentration, but only at t=30 mins as compared to the other 
animals in the AC Stim Group. This animal also had the smaller gauge electrode, as 
mentioned above, which may have decreased stimulation effectiveness/delivery. 
Rabbit 50: AC Stimulation Group 
This animal was started with a circuit input voltage of 4 volts peak-to-peak and 
exhibited twitching. The voltage was decreased until the twitching ceased, which was 
at 2 volts peak-to-peak. Each AC Stimulation Group animal thereafter was 
administered a Vin of approximately 2 volts peak-to-peak, which was adjusted slightly 
depending on how the animal tolerated stimulation. Additionally, due to the amount of 
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twitching upon administration of electrical stimulation, a higher-than-normal (as 
compared to the other experiments) amount of the octreotide drip was applied to wet 
the mucosa of the animal to decrease twitching. This resulted in the animal receiving a 
bit less of the oral octreotide drip for the duration of the experiment. During the 30 
minute blood draw, the artery was constricted, and therefore a cardiac stick was 
performed to obtain the 30 minute blood sample for serum concentration analysis. 
Rabbit 47: Negative DC Stimulation Group 
Prior to the start of the experiment, the animal exhibited a tiny prick on the tongue 
associated with tweezers utilized during intubation. We were concerned this could 
corrupt our concentration data if the prick was not fully clotted and octreotide seeped 
straight into the blood stream; however, this prick turned out to be inconsequential, as 
this rabbit exhibited the second-lowest octreotide concentration at 30 minutes in the 
Negative DC Stimulation Group. The hip electrode in this animal had become brittle 
for unknown reasons by the end of the experiment and broke at the skin when the 
alligator clip was detached. This animal did appear to have a significantly lower serum 
octreotide concentration than three of the other animals in the Negative DC Stimulation 
Group; however, one other animal (Rabbit 54) in this group did exhibit lower 
concentrations than Rabbit 47 at each time point, so it is difficult to say whether the 
brittle electrode affected octreotide absorption. However, after this electrode breakage, 
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it was determined that we should switch to a larger gauge wire for our electrodes for 
the remainder of the study, as mentioned above. 
Rabbit 63: Negative DC Stimulation Group 
This animal displayed signs of light anesthesia towards the end of the experiment, and 
consequently was administered an additional half dose of anesthesia. Additionally, this 
animal exhibited an unexplained green ooze at the skin where the hip electrode 
entered/exited the skin. This did not appear to affect serum octreotide concentration. 
Rabbit 60: Positive DC Stimulation Group 
At t=11 minutes, stimulation was ceased for approximately 2 seconds to adjust the oral 
electrode connection to the circuit. This did not appear to affect the concentration of 
serum octreotide, as this particular rabbit had concentrations very close to the mean and 
median values of the other animals in the group. 
6.3 Discussion 
Since octreotide is administered to patients with chronic conditions such as 
acromegaly, carcinoid syndrome, and chemotherapy-induced severe diarrhea, it is 
desirable to explore alternate routes of delivery (other than parenteral routes typically 
used), particularly if these alternate routes are accompanied with higher patient 
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compliance, ease of use, and less discomfort. Octreotide cannot be administered orally 
due to denaturation in the gastrointestinal tract and hepatic first-pass metabolism; with 
the aid of an applied local electrical current, orotransmucosal delivery may provide a 
means with which to effectively and non-invasively deliver octreotide to patients in a 
chronic manner. 
The findings from this pilot animal study were significantly positive and clearly 
demonstrate the ability of an applied electrical current to increase the serum 
concentration of sublingual octreotide in rabbits versus passive sublingual diffusion 
alone. Electrical stimulation of +4 mA direct current increased serum octreotide 
concentration by a factor of nine versus sublingual diffusion alone (p=0.023; 
statistically significant), and increased absorption rate by a factor of 28 (i.e., 2,700% 
increase in absorption rate) with high statistical significance (p-value of 0.0008) as 
compared to the Oral Baseline Absorption Group. For a direct current stimulus of -4 
mA, the serum concentration was increased by a factor of seven versus sublingual 
diffusion alone (p=0.08; non-statistically significant), and the rate of octreotide 
absorption increased by a factor of 19x with borderline significance (p=0.032) when 
compared with the Oral Baseline Absorption Group. Alternating current (20 Hz) 
stimulus with an average of 2.3 mA peak-peak across the rabbits was less effective than 
the direct current stimulation groups (3x increase in serum concentration and 10x 
increase of rate of concentration change (on average) as compared to the unstimulated 
oral absorption group, but not statistically significant due to large variations).  
65 
 
 
 
In one animal in the +DC group and one animal in the –DC group, a decrease in animal 
mucosal resistance was observed. In these experiments, this change in resistance 
appeared to be on the order of tens to hundreds of ohms; however, sufficient data was 
not collected for these two animals, or for other study animals to draw decisive 
conclusions on how mucosal resistance changes over time in the presence of an 
electrical field; however, other studies30 have shown a decrease in oral mucosa over 
time with the application of a direct current electric field. It is worth noting that this 
phenomena was not observed in any of the AC animals, and therefore may have played 
a role in the significant increase in octreotide absorption rate into the blood stream 
associated with both DC groups. 
The first stimulated experiment we performed was on Rabbit 46, and as noted in the 
Results section, this animal received a 100 kH 4 v peak-to-peak stimulation for the first 
18 minutes of the experiment due to stimulation system operator inexperience and 
error. Even when this animal was excluded from our calculations, however, the 
recalculated p value (0.092) was not significantly different than the original p value 
(0.091), and therefore the errors made with this particular animal did not have a 
significant impact on our overall outcomes and findings. This animal was also one of 
the four animals that received a smaller-gauge electrode wire.  
As mentioned in the Results section, one animal in the Negative DC Stimulation Group 
received a smaller-gauge electrode wire than the other animals in the group, and also 
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exhibited electrode breakage at the hip upon completion of the study. The p value was 
recalculated for the Negative DC Stimulation Group without this animal (0.093), and it 
was not found to be significantly different from the original p value calculated for this 
group (0.085). The other two animals that received a smaller-gauge electrode wire were 
in the Positive DC Stimulation Group, and since they had the lowest serum octreotide 
concentrations in this group, but the group was still statistically significant, a p value 
excluding these two animals was not calculated (since hypothetically their exclusion 
should further decrease the p value).  
Although the electrical stimulus increased the rate of absorption significantly, the 
baseline rate of oral absorption was relatively very low. In humans, the lower limit of 
therapeutic serum concentration is approximately 5.2 ng/ml (100 mcg dose). The 
percentage of therapeutic dose was calculated for each sublingual group (Table 10). We 
found that the Baseline group exhibited serum octreotide concentrations that were 
about 1.4% of know therapeutic serum concentrations (70 times less than therapeutic 
levels); the +DC group exhibited serum octreotide concentrations that were 13% of 
known therapeutic concentrations (8 times less than therapeutic levels); the -DC group 
exhibited serum concentrations that were about 10% of known therapeutic levels (10 
times less than therapeutic levels); and the AC group exhibited serum concentrations 
that were about 5% of known therapeutic levels (21 times less than therapeutic levels).  
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 Again, these results clearly demonstrate the ability of an applied electrical field to 
significantly increase sublingual octreotide diffusion into the blood stream, while 
showing promise that therapeutic serum octreotide concentrations could potentially be 
achieved via this route of delivery. Since diffusion is proportional to the concentration 
differences across a barrier, theoretically oral octreotide concentration can be increased 
in the saliva to make sublingual absorption more effective. 
Though the stimulated animals in our study did not exhibit serum concentrations of 
octreotide high enough to be therapeutically significant, there is evidence that 
extending the time of exposure to octreotide, as well as increasing the concentration of 
the oral drip may result in blood octreotide concentrations closer to therapeutically 
Comparison between Sublingual Diffusion Groups serum octreotide concentrations at 30 mins and 
therapeutic levels (5.2 ng/ml). Baseline group exhibited average serum levels that were 1.4% of 
known therapeutic concentrations; +DC exhibited average serum concentration at 30 minutes that 
was 13% of known therapeutic concentration; -DC exhibited average serum concentration at 30 
minutes that was 10% of therapeutic concentrations; and AC group exhibited average serum 
concentrations at 30 minutes that was 5% of known therapeutic concentrations.  
 
TABLE 10: Comparison Between Sublingual Diffusion Groups Serum Octreotide 
Concentrations and Known Therapeutic Serum Concentration 
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significant levels.25 Lau et al. showed that transdermal iontophoretic delivery of 
octreotide acetate at a concentration of 5 mg/ml and a current of 0.15 mA resulted in 
serum octreotide concentration of approximately 2.2 ng/ml after approximately 3 hours 
of exposure, with an apparent bioavailability of 8.1%. This concentration is only half 
the calculated lower limit of therapeutically significant serum octreotide concentration 
(~5.2 ng/ml for a dose of 100 mcg at 25 minutes). Since the stratum corneum is the 
main barrier to diffusion across the skin, sublingual delivery may be even more 
significant given the same concentration and exposure duration since the sublingual 
mucosa lacks a stratum corneum. Additionally, the most effective concentration of 
transdermally administered octreotide was 100 times more than the concentration 
utilized in our study, and the maximum current utilized was 46 times less than in our 
study. It follows that utilizing our system at the same currents delivered in our study 
with durations and concentrations similar to that of Lau, et al., compounded with the 
fact that our system delivers octreotide across a membrane which lacks a stratum 
corneum should result in more effective systemic octreotide delivery than our pilot 
study and the transdermal study by Lau et al. 
Additionally, Hau et al. showed that local transmucosal delivery of lidocaine through 
the buccal mucosa was significantly enhanced by utilizing a low-dc current (as in our 
study), coupled with electroporation (short, high voltage pulses) and absorption 
enhancement chemicals. It follows that both electroporation and/or enhancement 
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chemicals may potentially enhance systemic octreotide delivery in our system as well, 
and should be incorporated into future works. 
6.4 Limitations 
Although the outcomes of our experiments were largely positive and insightful, there 
are improvements (in addition to the mediating deviations from the protocol mentioned 
in the Results section) that could be made to enhance outcomes from future feasibility 
studies in the development of the SEP device.  
Our experiments were designed to only last for 30 minutes based on the fact that we 
preferred to only administer one dose of anesthesia to each animal, and one dose was 
expected to last for approximately 45 minutes (giving us a window of time to get the 
animal and system set up, perform the experiment, euthanize the animal and harvest 
tissue). When both the concentration data and the rate change of concentration data are 
examined, however, it appears that serum concentration levels in the stimulated 
animals was still increasing at the termination of the experiment (30 mins), and had we 
been able to continue oral drip and stimulation we believe serum octreotide 
concentrations would have increased as well – possibly to the point of statistical 
significance in the negative DC stimulation group and the AC stimulation group. 
Since the concentration gradient of octreotide across the sublingual mucosa plays a 
significant role in diffusion, it would be beneficial to perform an oral absorption study 
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with electrical stimulation utilizing octreotide acetate at higher concentrations to 
discern if achieving a therapeutic level of octreotide in the blood stream through 
sublingual absorption is feasible. 
For AC stimulation, capacitive properties of the animals were not taken into account in 
the design of the precision current source; however, since these groups did not display 
substantially higher concentrations of octreotide in the serum, further studies to correct 
this design flaw and explore concentration results are not necessary. 
Additionally, the oral electrode design was not ideal to ensure proper location of 
current delivery in the oral cavity. Development in the precision of this oral electrode 
should enhance the increase in octreotide absorption rate, and this factor most likely 
played a large role in the large disparities in serum concentrations between animals in 
the same stimulation groups. Likewise, oral drug delivery was not as precise as we 
would have liked, and could be improved upon by delivery via a local vehicle, either by 
a pill or patch, or by a method that would render a more precise rate of oral drip, such 
as an infusion pump. The localization factor of both these components likely 
contributed to the large disparities seen in concentrations between animals in the same 
stimulation groups. 
  
71 
 
 
 
7. CONCLUSIONS 
By applying three distinct electrical stimulation patterns to the oral mucosa of rabbits in 
the presence of octreotide acetate, we’ve discovered that a positive direct current of 
approximately 4 mA produces a statistically significant increase in the serum 
concentration of octreotide that is nine times greater than that of sublingual absorption 
alone. Additionally, when the rate changes of octreotide serum concentration between 
each sample time (absorption rates) were investigated, both the positive direct current 
and negative direct current groups exhibited statistically significant higher octreotide 
absorption rates when compared to sublingual absorption in the absence of electrical 
stimulation (28 times greater, p=0.0008; and 19 times greater, p=0.023 respectively). 
While therapeutic serum octreotide concentrations were not obtained in this study, we 
believe that by increasing oral electrode and drug delivery efficiency, increasing the 
duration of stimulation and sublingual octreotide exposure to about 4-5 hours, and 
utilizing an oral octreotide drip concentration of 5 mg/ml, therapeutic serum octreotide 
concentrations are feasible. Though the mechanisms involved in increased diffusion 
and decreased resistance in the mucosa as a result of an applied electrical field are not 
fully understood, key factors include the charge of the constituent that is administered 
and convective transport that affects movement of both neutral and charged particles 
(electroosmosis).8, 19 
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We discovered that a device such as the Sublingual Electronic Pill may be feasible in 
the sublingual delivery of peptides, proteins, and/or biologics, and shows enough 
promise to be investigated further. Additional studies that could aid in the successful 
development of this technology include: studies utilizing larger groups of animals; 
studies to investigate the effects of utilizing a higher concentration oral drip;25 studies 
that have a duration greater than 30 minutes, since it appears serum concentration was 
still increasing at this time; studies to determine feasibility in substances other than 
octreotide acetate; studies utilizing more efficient electrode and oral drug delivery 
designs; studies to assess synergistic benefits/efficiency of utilizing oral electrical 
stimulation in conjunction with absorption enhancers; studies utilizing direct current 
(iontophoresis) in tandem with high-voltage pulses (electroporation);19 and studies to 
determine ideal stimulation waveform and magnitude. This pilot study was a necessary 
first step in the direction of the successful realization of the SEP device. 
7.1 Funding 
This project is funded by the Department of Defense through DARPA (Defense 
Advanced Research Projects Agency) and USAMRMC (United States Army Medical 
Research and Material Command) ARO #58268-LS-DRP. 
7.2 Consultants  
John C. Criscione, Texas A&M University - Department of Biomedical Engineering 
73 
 
 
 
Maya Scott, Texas A&M University – Department of Veterinary Physiology & 
Pharmacology 
Michael Moreno, Texas A&M University – Department of Biomedical Engineering 
Kenith Meissner, Texas A&M University – Department of Biomedical Engineering 
Texas A&M University Comparative Medicine Program 
 Elizabeth Browder 
 Vincent Gresham 
 Andrea Taylor 
 Ryan Byrd 
TAMU Physics Department Electronics Shop 
Erwin Thomas III 
Texas A&M University Veterinary Medical Teaching Hospital 
 Stephen Lagutchik 
Sublingual Electronic Pill (SEP) Technologies, Inc.  
  
74 
 
 
 
REFERENCES 
1. Adams, G.P. and L.M. Weiner. Monoclonal antibody therapy of cancer. Nat. 
Biotechnol. 23(9):1147-1157, 2005. 
2. Ahsan, F., J. Arnold, E. Meezan, and D.J. Pillion. Enhanced bioavailability of 
calcitonin formulated with alkylglycosides following nasal and ocular 
administration in rats. Pharm. Res. 18(12):1742-1746, 2001. 
3. Analog Devices, Inc. [Internet]. Low cost low power instrumentation amplifier – 
AD620 Datasheet - Revision H; c2003-2011 [updated 2011 Jul; cited 2012 Jan 
12]. Available from: http://www.analog.com/en/specialty-amplifiers/ 
instrumentation-amplifiers/ad620/products/product.html 
4. Asgeirsson K.S., A. Agrawal, C. Allen, A. Hitch, I.O. Ellis, C. Chapman, K.L. 
Cheung, and J.F. Robertson. Serum epidermal growth factor receptor and HER2 
expression in primary and metastatic breast cancer patients. Breast Cancer Res. 
9(6):R75, 2007. 
5. Banga, A.K. and Y.W. Chien. Iontophoretic delivery of drugs: fundamentals, 
developments and biomedical applications. J. Controlled Release 7:1-24, 1988. 
6. Banga, A.K. and Y.W. Chien. Systemic delivery of therapeutic peptides and 
proteins. Int. J. Pharm. 48:15-50, 1988. 
7. Bauer, W., U. Briner, W. Doepfner, R. Haller, R. Huguenin, P. Marbach, T.J. 
Petcher, and J. Pless. SMS 201-995: a very potent and selective octapeptide 
analogue of somatostatin with prolonged action. Life Sci. 31(11):1133-1140, 1982. 
75 
 
 
 
8. Bejjani, R.A., C. Andrieu, C. Bloquel, M. Berdugo, D. BenEzra, and F. Behar-
Cohen. Electrically assisted ocular gene therapy. Surv. Ophthalmol. 52:196-208, 
2007. 
9. Benson, A.B. III, Ajani, J.A., Catalano, R.B., Engelking, C., Kornblau, S.M., 
Martenson, J.A. Jr., R. McCallum, E.P. Mitchell, T.M. O’Dorisio, E.E. Vokes, and 
S. Wadler. Recommended guidelines for the treatment of cancer treatment-induced 
diarrhea. J. Clin. Oncol. 22(14):2918-2926, 2004. 
10. Bouwstra, J. and M. Ponec. The skin barrier in healthy and diseased state. 
Biochim. Biophys. Acta. 1758:2080-2095, 2006. 
11. Campisi, G., L.I. Giannola, A.M. Florena, V. De Caro, A. Schumacher, R. 
Gottsche, C. Paderni, and A. Wolff. Bioavailability in vivo of naltrexone following 
transbuccal administration by an electronically-controlled intraoral device: a trial 
on pigs. J. Control. Release 145:214-220, 2010. 
12. Chien, Y.W., P. Lelawongs, O. Siddiqui, Y. Sun, and W.M. Shi. Facilitated 
transdermal delivery of therapeutic peptides and proteins by iontophoretic delivery 
devices. J. Control. Release 13:263-278, 1990. 
13. Ciach, T. and A. Moscicka-Studzinska. Buccal iontophoresis: an opportunity for 
drug delivery and metabolite monitoring. Drug Discov. Today 16:361-366, 2011. 
14. De Caro, V., G. Giandalia, M.G. Siragusa, F.M. Sutera, and L.I. Giannola. New 
prospective in treatment of Parkinson’s disease: studies on permeation of 
ropinirole through buccal mucosa. Int. J. Pharm. 429:78-83, 2012. 
76 
 
 
 
15. Feelders, R.A., L.J. Hofland, M.O. van Aken, S.J. Neggers, S.W.J. Lamberts, 
W.W. de Herder, and A.J. van der Lely. Medical therapy of acromegaly: efficacy 
and safety of somatostatin analogues. Drugs 69(16):2207-2226, 2009. 
16. Giannola, L.I., V. De Caro, G. Giandalia, M.G. Siragusa, C. Tripodo, A.M. 
Floreno, and G. Campisi. Release of naltrexone on buccal mucosa: permation 
studies, histological aspects and matrix system design. Eur. J. Pharm. Biopharm. 
67:425-433, 2007. 
17. Godin, B. and E. Touitou. Transdermal skin delivery: predictions for humans from 
in vivo, ex vivo and animal models. Adv. Drug Delivery Rev. 59:1152-1161, 2007. 
18. Guy, R.H., Y.N. Kalia, M.B. Delgado-Charro, V. Merino, A. Lopez, and D. 
Marro. Iontophoresis: electrorepulsion and electroosmosis. J. Control. Release 
64:129-132, 2000. 
19. Hau, J., Li, S.K., Liu, C., and W.W.Y. Kao. Electrically assisted delivery of 
macromolecules into the corneal epithelium. Exp. Eye Res. 89:934-941, 2009. 
20. Holbrook, K.A. and G.F. Odland. Regional differences in the thickness (cell 
layers) of the human stratum corneum: an ultrastructural analysis. J. Invest. 
Dermatol. 62:415-422, 1974. 
21. Jacobsen, J. Buccal iontophoretic delivery of antenolol-HCl employing a new in 
vitro three-champer permeation cell. J. Control. Release 70:83-95, 2001. 
22. Kalia, Y.N., A. Naik, J. Garrison, and R.H. Guy. Iontophoretic drug delivery. Adv. 
Drug Deliver. Rev. 56:619-658, 2004. 
77 
 
 
 
23. Kornblau, S., Benson, A.B. III, Catalano, R., Champlin, R.E., Engelking, C.E., 
Field, M., Ippoliti, C., Lazarus, H.M., Mitchell, E., Rubin, J., Stiff, P.J., Vokes, E., 
and S. Wadler. Management of cancer treatment-related diarrhea: issues and 
therapeutic strategies. J. Pain Symptom Manage. 19(2):118-129, 2000. 
24. Kutz, K., E. Nuesch, and J. Rosenthaler. Pharmacokinetics of SMS 201-995 in 
healthy subjects. Scand. J. Gastroenterol. 21:65-72, 1986. 
25. Lau, D.T.W., J.W. Sharkey, L. Petryk, F.A. Mancuso, Z. Yu, and F.L.S. Tse. 
Effect of current magnitude and drug concentration on iontophoretic delivery of 
octreotide acetate (Sandostatin®) in the rabbit. Pharm. Res. 11(12):1742-1746, 
1994. 
26. Madhav, N.V.S., A.K. Shakya, P. Shakya, and K. Singh. Orotransmucosal drug 
delivery systems: a review. J. Control. Release 140:2-11, 2009. 
27. Mannila, J., K. Jarvinen, J. Holappa, L. Matilaine, S. Auriola, and P. Jarho. 
Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility 
peptides: a study using cyclosporine A, alpha-cyclodextrin and quaternary chitosan 
N-betainate. Int. J. Pharm. 381:19-24, 2009. 
28. Mitchell, P. Erbitux diagnostic latest adjunct to cancer therapy. Nat. Biotechnol. 
22(4):363-4, 2004. 
29. Miyagishi, M. and K. Taira. siRNA becomes smart and intelligent. Nat. 
Biotechnol. 23(8):946-7, 2005. 
78 
 
 
 
30. Moscicka-Studzinska, A., E. Kijenska, and T. Ciach. Electroosmotic flow as a 
result of buccal iontophoresis – buccal mucosa properties. Eur. J. Pharm. 
Biopharm. 72:595-599, 2009. 
31. Naik, A., Y.N. Kalia, and R.H. Guy. Transdermal drug delivery: overcoming the 
skin’s barrier function. Pharm. Sci. Technol. Today 3(9):318-326, 2000. 
32. Ottesen, L.H., A. Flyvbjerg, P. Jakobsen, and F. Bendtsen. The pharmacokinetics 
of octreotide in cirrhosis and in healthy man. J. Hepatol. 26:1018-1025, 1997. 
33. Prausnitz, M.R. The effects of electric current applied to skin: a review for 
transdermal drug delivery. Adv. Drug Delivery Rev. 18:395-425, 1996. 
34. Scheuplein, R.J. and I.H. Blank. Permeability of the skin. Physiol. Rev. 51(4):702-
747, 1971. 
35. Scholz, O.A., A. Wolff, A. Schumacher, L.I. Giannola, G. Campisi, T. Ciach, and 
T. Velten. Drug delivery from the oral cavity: focus on a novel mechatronic 
delivery device. Drug Discov. Today 13:247-253, 2008. 
36. Senel, S., M.J. Rathbone, M. Cansiz, and I. Pather. Recent developments in buccal 
and sublingual delivery systems. Expert Opin. Drug Del. 9(6):615-628, 2012. 
37. Senel, S., M. Kremer, K. Nagy, and C. Squier. Delivery of bioactive peptides and 
proteins across oral (buccal) mucosa. Curr. Pharm. Biotechnol. 2:175-186, 2001. 
38. Singh, P., and H.I. Maibach. Iontophoresis in drug delivery: basic principles and 
applications. Crit. Rev. Ther. Drug Carrier Syst. 11:161-213, 1994. 
39. Sloan, J.B. and K. Soltani. Iontophoresis in dermatology. J. Am. Acad. Dermatol. 
15:671-684, 1986. 
79 
 
 
 
40. Tyle, P. Iontophoretic devices for drug delivery. Pharm. Res. 3(6):318-326, 1986. 
41. Whitton, J.T. and J.D. Everall. The thickness of the epidermis. Br. J. Dermatol. 
89:467-476, 1973. 
  
80 
 
 
 
VITA 
Christina Marie Bolch is a graduate of the Dwight Look College of Engineering at 
Texas A&M University where she received her Bachelor of Science degree in 
Biomedical Engineering (2007) and Master of Engineering in Biomedical Engineering 
(2010). She received her Doctor of Philosophy in Biomedical Engineering from Texas 
A&M University in 2012. Presently, she has one publication in press and one 
publication in submission, and is listed as a partial inventor on an issued patent. Her 
research interests include the role of mechanics in cardiovascular disease processes and 
device-based therapies for cardiovascular pathologies. She now works as a Project 
Engineer at CorInnova, Inc. where she continues to develop these ideas and therapies. 
Christina may be reached at 3120 TAMU, Department of Biomedical Engineering, 
Texas A&M University, College Station, TX 77843-3120. Her email address is 
stina1115@gmail.com. 
 
